Your browser doesn't support javascript.
loading
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial.
Subbiah, Vivek; Dumbrava, Ecaterina Ileana; Jiang, Yunfang; Thein, Kyaw Z; Naing, Aung; Hong, David S; Fu, Siqing; Piha-Paul, Sarina A; Tsimberidou, Apostolia M; Janku, Filip; Meric-Bernstam, Funda; Kurzrock, Razelle; Falchook, Gerald.
Afiliación
  • Subbiah V; 1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
  • Dumbrava EI; 4Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, Unit #455, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 USA.
  • Jiang Y; 1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
  • Thein KZ; 1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
  • Naing A; 1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
  • Hong DS; 1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
  • Fu S; 1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
  • Piha-Paul SA; 1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
  • Tsimberidou AM; 1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
  • Janku F; 1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
  • Meric-Bernstam F; 1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
  • Kurzrock R; 1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
  • Falchook G; 2Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California San Diego Moores Cancer Center, La Jolla, CA USA.
Exp Hematol Oncol ; 9: 7, 2020.
Article en En | MEDLINE | ID: mdl-32337094
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Exp Hematol Oncol Año: 2020 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Exp Hematol Oncol Año: 2020 Tipo del documento: Article Pais de publicación: Reino Unido